•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
Enliven Therapeutics (NASDAQ:ELVN) Stock Falls 4.5% Following Insider Selling
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Enliven Therapeutics to Present at Upcoming Investor Conferences
Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
BlackRock Inc. Invests $221.25 Million in Enliven Therapeutics, Inc. $ELVN
Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
Dimensional Fund Advisors LP Raises Holdings in Enliven Therapeutics, Inc. $ELVN
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Enliven Therapeutics, Inc. $ELVN is Avidity Partners Management LP’s 6th Largest Position
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants